Fraunhofer-Institut für Translationale Medizin und Pharmakologie (ITMP) / Fraunhofer Institute for Translational Medicine and Pharmacology
Research facility
Location:
Frankfurt am Main,
Germany (DE)
ISNI: -
ROR: https://ror.org/01s1h3j07
EFFICACY OF UST IN ACTIVE PSA IS INDEPENDENT FROM CONCOMITANT MTX USE, EVEN IN PATIENTS WITH MORE SEVERE SKIN PSORIASIS: SUBGROUP ANALYSIS FROM A RANDOMIZED PLACEBO-CONTROLLED INVESTIGATOR INITIATED CLINICAL TRIAL (2022)
Koehm M, Rossmanith T, Foldenauer AC, Kellner H, Kiltz U, Rech J, Burmester GR, et al.
Conference contribution
GPR40 Activation Abolishes Diabetes-Induced Painful Neuropathy by Suppressing VEGF-A Expression (2022)
Königs V, Pierre S, Schicht M, Welss J, Hahnefeld L, Rimola V, Lütjen-Drecoll E, et al.
Journal article
Key interactions in the trimolecular complex consisting of the rheumatoid arthritis-associated DRB1*04:01 molecule, the major glycosylated collagen II peptide and the T-cell receptor (2022)
Ge C, Weisse S, Xu B, Dobritzsch D, Viljanen J, Kihlberg J, Do NN, et al.
Journal article
Neither Add-on nor Withdrawal of Methotrexate Impacts Efficacy of IL12/23 Inhibition in Active PsA: Data from a Multicenter Investigator-initiated Randomized Placebo-controlled Clinical Trial on Arthritis, Dactylitis, Enthesitis, Psoriasis, QoL and Function (2021)
Koehm M, Rossmanith T, Foldenauer AC, Herrmann E, Kellner H, Kiltz U, Rech J, et al.
Conference contribution
IMPACT OF METHOTREXATE ON DISEASE PATTERN IN ACTIVE PSORIATIC ARTHRITIS PATIENTS ELIGIBLE FOR A RANDOMIZED CLINICAL TRIAL WITH USTEKINUMAB: COMPARATIVE BASELINE DATA FROM MULTICENTRE INVESTIGATOR-INITIATED MUST TRIAL (2020)
Rossmanith T, Koehm M, Kiltz U, Rech J, Burmester GR, Kellner H, Bulczak-Schadendorf A, et al.
Conference contribution